BioMEMS Resource Center
The BioMEMS Research Center (BMRC) is dedicated to advancing microfluidic technologies through research, collaboration, and education. It focuses on developing innovative diagnostic tools, cell and tissue microengineering, and fostering partnerships to translate microfluidic innovations into real-world applications.
Industries
Nr. of Employees
small (1-50)
BioMEMS Resource Center
Charlestown, Massachusetts, United States, North America
Products
Microfluidic CD4 T-cell counting chip
A microfluidic device architecture for counting CD4+ T cells from blood using flow-assisted affinity isolation, intended to support immune monitoring.
Herringbone microfluidic rare-cell isolation device
Microfluidic geometry employing chaotic mixing structures to enhance contact between target cells and capture surfaces for isolation of rare cells from blood.
Microfluidic granulocyte monitoring platform
A platform for monitoring granulocyte levels in clinical settings using microfluidic sampling and analysis.
Microfluidic RNA isolation device for small samples
Microfabricated device and protocol enabling isolation of high-quality total RNA from very small numbers of cells for molecular assays.
High-density microfluidic cell array platform
A microfluidic array system for arranging and assaying large numbers of primary cells in co-culture for high-throughput physiology studies.
Organ-on-chip devices (liver, brain)
Microengineered organotypic devices and oxygenation/co-culture methods to support tissue-specific function for research and industrial applications.
Microfluidic CD4 T-cell counting chip
A microfluidic device architecture for counting CD4+ T cells from blood using flow-assisted affinity isolation, intended to support immune monitoring.
Herringbone microfluidic rare-cell isolation device
Microfluidic geometry employing chaotic mixing structures to enhance contact between target cells and capture surfaces for isolation of rare cells from blood.
Microfluidic granulocyte monitoring platform
A platform for monitoring granulocyte levels in clinical settings using microfluidic sampling and analysis.
Microfluidic RNA isolation device for small samples
Microfabricated device and protocol enabling isolation of high-quality total RNA from very small numbers of cells for molecular assays.
High-density microfluidic cell array platform
A microfluidic array system for arranging and assaying large numbers of primary cells in co-culture for high-throughput physiology studies.
Organ-on-chip devices (liver, brain)
Microengineered organotypic devices and oxygenation/co-culture methods to support tissue-specific function for research and industrial applications.
Services
Hands-on and instructional programs covering microfabrication, device operation, assay protocols, and best practices for researchers.
Provision of state-of-the-art microfabrication and biological facilities to support device fabrication, testing, and biological assays.
Support for invention disclosure, patent filing, and commercialization pathways, including partnership and licensing facilitation with external technology transfer offices.
Hands-on and instructional programs covering microfabrication, device operation, assay protocols, and best practices for researchers.
Provision of state-of-the-art microfabrication and biological facilities to support device fabrication, testing, and biological assays.
Support for invention disclosure, patent filing, and commercialization pathways, including partnership and licensing facilitation with external technology transfer offices.
Expertise Areas
- Microfluidics and lab-on-a-chip systems
- Cell and tissue microengineering
- Circulating tumor cell isolation and analysis
- Point-of-care diagnostics for global health
Key Technologies
- Microfluidics
- Inertial focusing
- Deterministic particle separation
- Magnetic cell sorting
News & Updates
Spin-offs from BMRC work
Several spin-offs have emerged from BMRC work, including Verinata Health, which was acquired by Illumina for $450 million, and Daktari, which is testing a CD4 chip in Africa. Other companies like Firefly BioWorks and Hurel have also benefited from collaborations with BMRC.
Spin-offs from BMRC work
Several spin-offs have emerged from BMRC work, including Verinata Health, which was acquired by Illumina for $450 million, and Daktari, which is testing a CD4 chip in Africa. Other companies like Firefly BioWorks and Hurel have also benefited from collaborations with BMRC.